Tonira Pharma Ltd - Stock Valuation and Financial Performance

Name: Tonira Pharma
Brand: Tonira Pharma

BSE: 530155 | NSE: | Pharmaceuticals & Drugs | Small Cap

Place order

BSE Share Price
Not Listed

DeciZen - make an informed investing decision on Tonira Pharma

Based on:

Data

M-Cap below 100cr DeciZen not available

Tonira Pharma stock performance -

PE Chart Key Ratios

P/E Ratio (SA):

0.00

Market Cap:

15.7 Cr.

52-wk low:

52-wk high:

19.9

Is an attractive stock to invest in?

1. Is a good quality company?

Data is not available for this company.

2. Is undervalued or overvalued?

No data found

3. Is a good buy now?

No data found

10 Year X-Ray of Tonira Pharma:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'02	Mar'03	Mar'04	Mar'05	Mar'06	Mar'07	Mar'08	Mar'09	Mar'10	Mar'11	TTM
ROCE % ⓘ	13.7%	17.5%	2.5%	6.7%	7.5%	7.5%	-4.7%	10.8%	6.2%	-1.8%	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	19.4	24	26.2	22.5	29.4	36.8	32.6	41.3	36.9	30.2	33
Sales YoY Gr.	-	23.3%	9.1%	-13.8%	30.3%	25.2%	-11.5%	26.8%	-10.7%	-18.1%	-
Adj EPS ⓘ	2.4	3.4	0.1	1.8	2.3	2.2	-4.3	2.5	0.8	-3.8	-4.2
YoY Gr.	-	44.5%	-96.5%	1425%	25.1%	-6.1%	-300.5%	NA	-66.9%	-565.9%	-
BVPS (₹) ⓘ	15.4	16.5	17.5	21	23	24.7	17.5	16.4	18.1	15.4	12.5
Adj Net Profit ⓘ	1.9	2.7	0.1	1.5	1.8	1.7	-3.4	2	0.7	-3	-3
Cash Flow from Ops. ⓘ	2.8	4.5	2.7	3.7	-0.6	5.1	-7.1	3.8	7.5	-0.9	-
Debt/CF from Ops. ⓘ	2.1	0.8	2.5	4.2	-37.7	3.9	-4.1	7.1	4.2	-39.4	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	5%	0.6%	-2.5%	-18.1%
Adj EPS ⓘ	-205.4%	-210.8%	NA	-565.9%
BVPSⓘ	0%	-7.7%	-4%	-14.5%
Share Price	-	-	-	-

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'02	Mar'03	Mar'04	Mar'05	Mar'06	Mar'07	Mar'08	Mar'09	Mar'10	Mar'11	TTM
Return on Equity % ⓘ	16.2	21	0.7	9.4	10.3	8.9	-20	14.4	4.8	-22.8	-30.2
Op. Profit Mgn % ⓘ	6.7	7.3	5.3	17.4	21.8	19.3	-3.1	23.9	17.2	8.1	0.7
Net Profit Mgn % ⓘ	9.7	11.4	0.4	6.4	6.2	4.6	-10.5	4.8	1.8	-10.1	-10
Debt to Equity ⓘ	0.5	0.3	0.5	0.9	1.2	1	2.1	2.1	2.2	3	-
Working Cap Days ⓘ	219	182	157	186	185	189	240	211	248	314	269
Cash Conv. Cycle ⓘ	122	80	64	93	97	100	128	100	131	187	203

Recent Performance Summary

No data to display

Return on Equity has declined versus last 3 years average to %

Sales growth has been subdued in last 3 years %

Sales growth is not so good in last 4 quarters at %

Latest Financials - Tonira Pharma Ltd.

	Standalone	Consolidated
TTM EPS (₹)	-4.2	-2.6
TTM Sales (₹ Cr.)	33.5	30.2
BVPS (₹.) ⓘ	12.5	15.3
Reserves (₹ Cr.) ⓘ	2	4
P/BV ⓘ	1.58	1.29
PE ⓘ	0.00	0.00

From the Market
52 Week Low / High (₹)	19.00 / 19.90
All Time Low / High (₹)	0.80 / 50.30
Market Cap (₹ Cr.)	15.7
Equity (₹ Cr.)	7.9
Face Value (₹)	10
Industry PE ⓘ	47.8

Management X-Ray of Tonira Pharma:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Tonira Pharma

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Tonira Pharma

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'02	Mar'03	Mar'04	Mar'05	Mar'06	Mar'07	Mar'08	Mar'09	Mar'10	Mar'11
Sales	19.44	23.96	26.15	22.54	29.37	36.78	32.56	41.28	36.86	30.18
Operating Expenses ⓘ	18.14	22.22	24.89	18.65	23.60	29.92	33.57	33.03	30.55	27.80
Manufacturing Costs	2.93	3.69	3.80	3.73	4.19	4.82	5.09	4.50	3.96	4.77
Material Costs	11.85	14.27	13.58	9.22	12.23	15.85	18.77	18.53	18.19	15.63
Employee Cost	1.37	1.71	1.94	2.31	3.19	4.12	4.89	4.11	4.52	4.33
Other Costs ⓘ	2	2.55	5.57	3.39	3.99	5.13	4.82	5.88	3.89	3.06
Operating Profit ⓘ	1.30	1.74	1.26	3.89	5.77	6.87	-1.01	8.25	6.31	2.38
Operating Profit Margin (%)	6.7%	7.3%	4.8%	17.2%	19.6%	18.7%	-3.1%	20.0%	17.1%	7.9%
Other Income ⓘ	2.02	2.52	1.11	0.39	0.60	0.21	0.62	0.48	0.75	1.62
Interest ⓘ	0.84	0.51	0.55	0.47	1.25	1.81	2.10	3.60	2.88	3.14
Depreciation ⓘ	1	1.13	1.27	1.43	2.44	2.57	2.77	2.80	2.84	3.07
Exceptional Items ⓘ	0	0	0	0	0	0	-3.92	-2.69	0	0
Profit Before Tax ⓘ	1.48	2.62	0.55	2.38	2.68	2.70	-9.18	-0.35	1.34	-2.21
Tax ⓘ	-0.41	-0.11	-0.17	0.72	0.96	1.06	-3.36	0.39	0.32	-0.12
Profit After Tax	1.89	2.73	0.72	1.66	1.72	1.64	-5.83	-0.74	1.02	-2.08
PAT Margin (%)	9.7%	11.4%	2.8%	7.4%	5.9%	4.5%	-17.9%	-1.8%	2.8%	-6.9%
Adjusted EPS (₹)	2.4	3.4	0.9	2.1	2.2	2.1	-7.3	-0.9	1.3	-2.6
Dividend Payout Ratio (%)	0%	29%	0%	0%	0%	0%	0%	0%	0%	0%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'02	Mar'03	Mar'04	Mar'05	Mar'06	Mar'07	Mar'08	Mar'09	Mar'10	Mar'11
Equity and Liabilities
Shareholders Fund	12.71	13.36	14.09	16.72	18.44	20.08	14.25	13.19	14.34	12.26
Share Capital ⓘ	7.94	7.94	7.94	7.94	7.94	7.94	7.94	7.94	7.94	7.94
Reserves ⓘ	4.77	5.42	6.14	8.77	10.50	12.14	6.31	5.25	6.40	4.32
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	5.77	3.56	6.77	15.30	21.40	19.68	28.90	27.02	31.29	36.73
Long Term Debt	5.77	3.56	6.77	15.30	21.40	19.68	28.90	27.02	31.29	36.73
Short Term Debt	0	0	0	0	0	0	0	0	0	0
Trade Payables	3.05	3.62	3.75	4.73	4.57	7.33	7.92	9.20	6.52	5.13
Others Liabilities ⓘ	-0.39	1.61	0.87	0.54	1.53	2.78	-0.38	1.21	0.79	0.62
Total Liabilities ⓘ	21.14	22.16	25.48	37.29	45.94	49.88	50.69	50.62	52.95	54.74
Fixed Assets
Gross Block	7.69	7.73	15.64	17.64	37.49	40.52	41.45	42.07	45.24	46.86
Accumulated Depreciation	3.42	4.06	6.42	7.78	10.19	12.73	15.26	17.94	20.68	23.45
Net Fixed Assetsⓘ	4.27	3.67	9.22	9.86	27.30	27.79	26.19	24.13	24.55	23.40
CWIP ⓘ	3.95	5.54	4.43	14.49	0	0	0	0.09	0.54	1.21
Investmentsⓘ	0	0	0	0	0.12	0.04	0.04	0.04	0.14	0.14
Inventories	9.08	7.05	7.77	9.21	10.72	15.23	13.79	13.13	11.73	15.56
Trade Receivables	1	1.17	2.43	1.91	5.57	4.03	5.42	7.47	6.33	3.81
Cash Equivalents	0.24	0.37	0.58	0.70	0.27	0.35	1.58	0.55	3.08	2.22
Others Assetsⓘ	2.59	4.35	1.05	1.11	1.96	2.44	3.67	5.21	6.57	8.40
Total Assets ⓘ	21.14	22.16	25.48	37.29	45.94	49.88	50.69	50.62	52.95	54.74

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'02	Mar'03	Mar'04	Mar'05	Mar'06	Mar'07	Mar'08	Mar'09	Mar'10	Mar'11
Cash Flow From Operating Activity ⓘ	2.77	4.46	2.69	3.68	-0.57	5.07	-7.14	3.82	7.45	-0.93
PBT ⓘ	1.48	2.62	0.55	2.37	2.64	1.64	-5.83	2.34	1.34	-2.21
Adjustment ⓘ	2.35	1.84	1.94	1.71	4.40	5.15	1.03	7.67	5.17	4.97
Changes in Working Capital ⓘ	-0.32	0.4	0.61	-0.11	-6.65	-0.11	-0.47	-3.82	1.38	-3.45
Tax Paid ⓘ	0	0	0	-0.01	0	-0.04	-0.03	-0.08	-0.42	-0.19
Cash Flow From Investing Activity ⓘ	-1.48	-2.11	-5.68	-12.08	-5.62	-3.27	-0.85	-0.72	-3.82	-2.63
Capex	-1.48	-2.11	-5.68	-12.08	-5.50	-3.35	-0.85	-0.72	-3.72	-2.63
Net Investments	0	0	0	0	-0.12	0.08	0	0	0	0
Others ⓘ	0	0	0	0	0	0	0	0	-0.10	0
Cash Flow From Financing Activityⓘ	-1.26	-2.21	3.21	8.53	6.11	-1.72	9.22	-4.12	-1.10	2.71
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	0	0	0	0	0	-1.37	3.52	-0.52	1.51	4.04
Interest Paid ⓘ	0	0	0	0	0	0	0	-3.60	-2.61	-1.33
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	-1.26	-2.21	3.21	8.53	6.11	-0.35	5.70	0	0	0
Net Cash Flow ⓘ	0.02	0.13	0.21	0.12	-0.08	0.08	1.22	-1.03	2.53	-0.86

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'02	Mar'03	Mar'04	Mar'05	Mar'06	Mar'07	Mar'08	Mar'09	Mar'10	Mar'11
Ratios
ROE (%)	16.99	21.56	5.35	10.87	9.85	8.65	-34.82	-5.54	7.48	-15.65
ROCE (%)	13.23	18.06	5.89	10.82	10.97	11.41	-17.27	7.83	9.86	1.97
Asset Turnover Ratio	0.97	1.13	1.14	0.73	0.72	0.79	0.66	0.82	0.72	0.56
PAT to CFO Conversion(x)	1.47	1.63	3.74	2.22	-0.33	3.09	N/A	N/A	7.3	N/A
Working Capital Days
Receivable Days	28	16	24	35	46	46	52	56	68	61
Inventory Days	151	120	99	135	122	125	159	118	123	164
Payable Days	96	85	99	168	139	137	148	141	100	71

Tonira Pharma Ltd Stock News

Tonira Pharma Ltd FAQs

What is the share price of Tonira Pharma?

Company share prices are keep on changing according to the market conditions. The closing price of Tonira Pharma on 01-Jan-1970 05:30 is ₹0.00.

What is the market cap of Tonira Pharma?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 01-Jan-1970 05:30 the market cap of Tonira Pharma stood at ₹15.69.

What is the P/E ratio of Tonira Pharma?

The latest P/E ratio of Tonira Pharma as of 01-Jan-1970 05:30 is 0.00.

What is the P/B ratio of Tonira Pharma?

The latest P/B ratio of Tonira Pharma as of 01-Jan-1970 05:30 is 1.58.

What is the 52-week high and low of Tonira Pharma?

The 52-week high of Tonira Pharma is ₹19.90 and the 52-week low is ₹19.00.

What is the TTM revenue of Tonira Pharma?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Tonira Pharma is ₹33.49 ( Cr.) .

About Tonira Pharma Ltd

Tonira Pharma incorporated, in 1992, is engaged in the business of manufacturing and marketing of Active Pharmaceutical Ingredients (APIs) and intermediates.

The company's manufacturing locations at Nandesari and Ankleshwar are inspected and approved by PMDA Japan. With the USFDA approval of the Nandesari plant and PMDA Japan approvals of both the plants, the company will now have access to regulated markets for its APIs.

Tonira operates a state-of-the-art R&D Center at Nandesari, Vadodara District in Gujarat. The centre is continuously developing newer value-added APIs through innovative and cost-effective processes.

Tonira undertakes contract synthesis both on exclusive and non-exclusive basis. The company has the capability to provide contract research and manufacturing services to its customers.

Products

APIs- Under this, the company manufactures Atenolo, Aceclofenac, Benzbromarone, Benzarone, Desloratadine, Ebastine, Famotidine, Glimepiride, Loratadine, Meloxicam, Mosapride Citrate, Nifedipine, Ofloxacin, Quetiapine Fumarate, Sodium Alendronate, Tramadol HCI, Tamsulosin HCI and Zolpidem Tartrate.

Recognitions/Achievements

Tonira Pharma has received WHO-GMP approval for its manufacturing facility.
The company is recipient of export award for two successive years from DGFT.
Its R&D centre is recognized by Department of Science & Technology, Government of India.
The company has been recognised as an Export House by Government of India.